# Tianshu Liu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/tianshu-liu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,094 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 49 |
| i10-index | 177 |
| Last Known Institution | Sun Yat-sen University |
| OpenAlex ID | https://openalex.org/A5100677110 |
| ORCID iD | https://orcid.org/0000-0002-2318-2869 |
| Works | 384 |

## Researcher papers

- [Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/regorafenib-plus-best-supportive-care-versus-placebo-plus-best-supportive-care/)
- [Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://scholariq.org/papers/effect-of-camrelizumab-vs-placebo-added-to-chemotherapy-on-survival-and/)
- [Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-for-her2/)
- [Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study](https://scholariq.org/papers/camrelizumab-versus-investigator-s-choice-of-chemotherapy-as-second-line-therapy/)
- [Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma](https://scholariq.org/papers/nivolumab-combination-therapy-in-advanced-esophageal-squamous-cell-carcinoma/)
- [Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)](https://scholariq.org/papers/guidelines-for-the-diagnosis-and-treatment-of-primary-liver-cancer-2022-edition/)
- [Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/tucidinostat-plus-exemestane-for-postmenopausal-patients-with-advanced-hormone/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

## Researcher university

- [Sun Yat-sen University](https://scholariq.org/institutions/sun-yat-sen-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.